Ireland· IE-PA-EU/1/10/614/002-003
Menveo powder and solution for solution for injection
A meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert product containing meningococcal group y oligosacchardie + meningococcal group a oligosaccharide + meningococcal group c oligosaccharide + meningococcal group w-135 oligosaccharide, registered in Ireland by Glaxosmithkline Vaccines S.r.l.. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH08 (meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AH08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Meningococcal group y oligosacchardie + Meningococcal group a oligosaccharide + Meningococcal group c oligosaccharide + Meningococcal group w-135 oligosaccharide
- Manufacturer
- Glaxosmithkline Vaccines S.r.l.
- Country
- Ireland (IE)
- ATC code
- J07AH08
- ATC class
- Meningokokken A, C, Y, W-135, tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/10/614/002-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH08
Meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert, as other registers publish it.
- CanadaMENACTRASANOFI PASTEUR LIMITED
- PolandMenQuadfiSanofi Winthrop Industrie
- FinlandMenQuadfiSanofi Winthrop Industrie
- BelgiumMenQuadfiSanofi Winthrop Industrie
- IcelandMenQuadfiSanofi Winthrop Industrie
- DenmarkMenQuadfiSanofi Winthrop Industrie
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
- CzechiaMENQUADFISanofi Winthrop Industrie, Gentilly
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9072763-5fbc-4176-83dd-a6bf2a8a0fad GET /v1/drugs/d9072763-5fbc-4176-83dd-a6bf2a8a0fad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solution for solution for injection",
"routes": [
"Intramuscular use"
],
"source": "hpra",
"atc_all": [
"J07AH",
"J07AH08"
],
"strength": null,
"pa_number": "EU/1/10/614/002-003",
"substances": [
"Meningococcal group y oligosacchardie",
"Meningococcal group a oligosaccharide",
"Meningococcal group c oligosaccharide",
"Meningococcal group w-135 oligosaccharide"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about meningokokken a, c, y, w-135, tetravalent, gereinigtes polysaccharid-antigen, konjugiert.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.